Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
source: pixabay.com

Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars

According to a story from ankylosingspondylitisnews.com, a significant proportion of patients stopped taking a biosimilar for infliximab within six months of transitioning to the new medication. This suggests that the…

Continue Reading Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Source: Pixabay.com

New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising

According to a story from The Irish Times, a new campaign is encouraging people with the rare lung condition idiopathic pulmonary fibrosis to keep exercising. The campaign is centered around…

Continue Reading New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold
source: pixabay.com

Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold

According to a story from genengnews.com, the pharmaceutical company Solid Biosciences is pledging to continue developing its investigation drug candidate SGT-001 for Duchenne muscular dystrophy. This is despite its clinical…

Continue Reading Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold
A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis
source: pixabay.com

A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis

According to a story from Neurology Advisor, a retired physician experienced the challenges of being a rare disease patient first hand after being diagnosed with primary periodic paralysis thanks to…

Continue Reading A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis
Treatment for Hereditary Angiodema Gets Marketing Approval From the EMA
source: pixabay.com

Treatment for Hereditary Angiodema Gets Marketing Approval From the EMA

According to a recent story from pm360online.com, the pharmaceutical company Shire announced that the marketing application for its drug product lanadelumab has gained approval from the European Medicines Agency (EMA).…

Continue Reading Treatment for Hereditary Angiodema Gets Marketing Approval From the EMA
An Experimental Drug Was Helping A Girl With Dravet Syndrome. Will She Lose Access After the Trial?
source: pixabay.com

An Experimental Drug Was Helping A Girl With Dravet Syndrome. Will She Lose Access After the Trial?

According to a recent story from CityNews Toronto, Alara Ozkose's Dravet syndrome was preventing her from being able to live a life that was even close to normal. She was…

Continue Reading An Experimental Drug Was Helping A Girl With Dravet Syndrome. Will She Lose Access After the Trial?
A New Sickle Cell Diseases Drug Has Been Awarded Orphan Drug Status by the US and EU
Source: Pixabay

A New Sickle Cell Diseases Drug Has Been Awarded Orphan Drug Status by the US and EU

A new drug called Altemia is being developed to treat sickle cell diseases in children, reports BioPortfolio. It has recently been awarded Orphan Drug designation in both the United States…

Continue Reading A New Sickle Cell Diseases Drug Has Been Awarded Orphan Drug Status by the US and EU
The Role of Microbial Sequencing in Understanding the Causes of Airway Inflammatory Diseases
Source: Pixabay

The Role of Microbial Sequencing in Understanding the Causes of Airway Inflammatory Diseases

Researchers at Northern Arizona University (NAU) are using microbial sequencing to better understand the causes of airway inflammatory diseases, including chronic rhinosinutsitis and cystic fibrosis. They hope that by studying…

Continue Reading The Role of Microbial Sequencing in Understanding the Causes of Airway Inflammatory Diseases
A Potential Treatment for Pulmonary Infection in Cystic Fibrosis has Been Awarded Patent Status
Source: Pixabay

A Potential Treatment for Pulmonary Infection in Cystic Fibrosis has Been Awarded Patent Status

A potential treatment of pulmonary infection for patients with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) has just been awarded U.S. patent status, reports Medicalxpress. Dr Daniel Hassett, a researcher…

Continue Reading A Potential Treatment for Pulmonary Infection in Cystic Fibrosis has Been Awarded Patent Status
Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU
source: pixabay.com

Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU

According to a story from mrknewsroom.com, the pharmaceutical companies Merck and AstraZeneca recently announced that the marketing application for the investigational drug olaparib (brand name Lynparza) was recently certified for…

Continue Reading Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU